A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
1996

Docetaxel for Advanced Breast Cancer

Sample size: 72 publication Evidence: moderate

Author Information

Author(s): I Adachi, T Watanabe, S Takashima, M Narabayashi, N Horikoshi, H Aoyama, T Taguchi

Primary Institution: National Cancer Center Hospital

Hypothesis

The study aims to evaluate the anti-tumor activity, time to progression, and clinical toxicity of docetaxel in patients with advanced or recurrent breast cancer.

Conclusion

Docetaxel shows potent activity against metastatic breast cancer and is considered safe at a dose of 60 mg/m².

Supporting Evidence

  • Five patients obtained a complete response and 27 a partial response.
  • The overall response rate was 44.4%.
  • Leucocytopenia and neutropenia were the major toxicities, occurring in 78.9% and 85.9% of patients respectively.
  • The median duration of response was 110 days.
  • 31.3% of patients did not experience disease progression during the study.

Takeaway

This study tested a new cancer drug called docetaxel on patients with advanced breast cancer, and it helped many of them feel better.

Methodology

Patients received at least two cycles of docetaxel 60 mg/m² intravenously at 3-4 week intervals, and their responses were evaluated.

Potential Biases

Potential bias due to the study being conducted at multiple hospitals and the involvement of a monitoring committee.

Limitations

The study had a relatively small sample size and was limited to patients with specific eligibility criteria.

Participant Demographics

Patients aged 15-80 years with performance status (PS) of 0-2.

Statistical Information

Confidence Interval

95% CI 32.7-56.6%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication